Амиксин®

General characteristics. Structure:

International unlicensed name: тилорон
Chemical name: dihydrochloride 2,7-bis-[2 (diethyl amines) - etoks] - fluorene - 9 - it
Dosage form: tablets, film coated

Active agent: тилорон (тилаксин) — 60 mg or 125 mg.
Excipients:
Kernel: potato starch, cellulose microcrystallic, povidone (коллидон 30), calcium stearate, croscarmellose sodium (primelloza)
Cover: a gipromelloz (gidroksipropilmetiltsellyuloz), titanium dioxide, a macrogoal 4000 (polyethyleneglycol 4000), polysorbate 80 (twin 80), quinolinic yellow E 104, sikovit yellow-orange 85 E 110.

 

Description
Tablets, film coated orange color, round, biconvex. On a break of orange color, insignificant impregnations of orange and white color are allowed.

Pharmacological properties:

Pharmacodynamics. The low-molecular synthetic inductor of interferon stimulating education in an organism of interferon an alpha, a beta and scale. The main producers of interferon in response to introduction of a tiloron are intestines epithelium cells, hepatocytes, T lymphocytes, neutrophils and granulocytes. After intake at most of products of interferon intestines — a liver — blood are defined by 4–24 h in the sequence.
^{Амиксин®} has immunomodulatory and antiviral effect.
In leukocytes of the person induces interferon synthesis. Stimulates stem cells of marrow, depending on a dose strengthens antibodyformation, reduces immunosuppression degree, recovers ratios of T-suppressors and T-helperov. It is effective against various viral infections, including, against influenza viruses, other acute respiratory viral infections, viruses of hepatitis and gerpesvirus. The mechanism of anti-virus action is connected with inhibition of broadcast of virus-specific proteins in the infected cells therefore the reproduction of viruses is suppressed.

Pharmacokinetics. After intake it is quickly soaked up from digestive tract. Bioavailability — 60%. About 80% of drug contact proteins of plasma. Drug practically in not changed look through intestines (70%) and through kidneys (9%) is removed. An elimination half-life (T1/2) — 48 h. Drug is not exposed to biotransformation and does not collect in an organism.

Indications to use:

At adults, treatment and prevention of flu, other SARS, treatment of a viral hepatitis, And, In and With; treatment of a herpes and Cytomegaloviral infection; as a part of complex therapy of infectious and allergic and viral encephalomyelitis (multiple sclerosis, a leukoencephalitis, uveoentsefalit, etc.), as a part of complex therapy of urogenital and respiratory clamidiosis, in complex therapy of a pulmonary tuberculosis;
At children, 7 years — for treatment of flu and other SARS are more senior.

Route of administration and doses:

Amiksin accept inside, after food.

At adults:
For nonspecific prevention of a viral hepatitis, And — 125 mg once a week within 6 weeks.
For treatment of a viral hepatitis, And — in the first days on 125 mg 2 times, then on 125 mg in 48 h. On a course — 1,25 g (10 tablets).
For treatment of an acute hepatitis In — the first two days on 125 mg, then 125 mg in 48 hours, on a course of treatment — 2 g (16 tablets). At the long course of hepatitis B — on 125 mg 2 times a day in the first day, then on 125 mg in 48 hours. On a course of treatment — 2,5 g (20 tablets).
At chronic hepatitis B — an initial phase of treatment (2,5 g — 20 tablets) — the first two days on 125 mg 2 times a day, then 125 mg in 48 hours. A continuation phase (from 1,25 g — 10 tablets to 2,5 g — 20 tablets) — on 125 mg a week. A course dose ^{of Amiksina®} from 3,75 g to 5 g, duration of therapy of 3,5-6 months depending on results of the biochemical, immunological, morphological researches reflecting a process degree of activity.
At an acute hepatitis With — on 125 mg a day the first 2 days of treatment, then on 125 mg in 48 hours. A course of treatment — 2,5 g (20 tablets).
At chronic hepatitis C — an initial phase of treatment (2,5 g — 20 tablets) — the first two days on 125 mg 2 times a day, then 125 mg in 48 hours. A continuation phase (2,5 g — 20 tablets) — on 125 mg a week. A course dose ^{of Amiksina®} — 5 g, therapy duration — 6 months depending on results of biochemical, immunological, morphological markers of activity of process.
At complex therapy of neuroviral infections — on 125–250 mg a day the first 2 days of treatment, then on 125 mg in 48 hours. A dose 3–4 weeks establish individually, a course of treatment.
For treatment of flu and other SARS — on 125 mg a day the first 2 days of treatment, then on 125 mg in 48 hours. On a course — 750 mg (6 tablets).
For prevention of flu and other SARS — on 125 mg once a week within 6 weeks. On a course — 750 mg (6 tablets).
For treatment of a herpes, Cytomegaloviral infection — the first two days on 125 mg, then in 48 hours on 125 mg. A course dose — 1,25 — 2,5 g (10 — 20 tablets).

At urogenital and respiratory clamidiosis — the first two days on 125 mg, then in 48 hours on 125 mg. Course dose of-1,25 g (10 tablets).
At complex therapy of a pulmonary tuberculosis — on 250 mg the first two days of treatment, further on 125 mg in 48 hours. A course dose — 2,5 g (20 tablets).
At children, 7 years at not complicated forms of flu and other SARS are more senior — on 60 mg for the 1st, 2nd and 4th day from an initiation of treatment once a day. A course dose — 180 mg (3 tablets). At emergence of complications of flu or others and a SARS - on 60 mg once a day on the 1st, 2nd,
The 4th and 6th day from an initiation of treatment. A course dose — 0,24 g (4 tablets).

Side effects:

Allergic reactions, the dispepsichesky phenomena, short-term fever are possible.

Interaction with other medicines:

Let's combine with antibiotics and medicines of traditional treatment of viral and bacterial diseases. Clinically significant influence ^{of Amiksina®} with antibiotics and means of traditional treatment of viral and bacterial diseases is not revealed.

Contraindications:

Hypersensitivity to drug. Period of pregnancy and lactation. Children's age up to 7 years.

Overdose:

Cases of overdose of drug are not known.

Storage conditions:

List B. In the dry place protected from light, at a temperature not above 30 °C. To store in the place, unavailable to children. A period of validity - 3 years. Not to apply after the period of validity specified on packaging.

Issue conditions:

Without recipe

Packaging:

Tablets, film coated 60 mg, 125 mg.
On 6 or 10 tablets in a blister strip packaging; on 6, 10 or 20 tablets in bank of polymeric.
1 either 2 blister strip packagings or to 1 bank polymeric together with the application instruction in a pack from a cardboard.